Profile data is unavailable for this security.
About the company
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The Company operates under one segment which develops pharmaceutical products. The Company's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The Company's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.
- Revenue in USD (TTM)2.01m
- Net income in USD4.09m
- Incorporated1987
- Employees8.00
- LocationSeelos Therapeutics Inc300 PARK AVENUE, 2ND FLOORNEW YORK 10022United StatesUSA
- Phone+1 (646) 293-2100
- Fax+1 (858) 436-8155
- Websitehttps://seelostherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Pharmacology (USA) Ltd | 0.00 | -105.18k | 99.96k | 0.00 | -- | -- | -- | -- | -0.0009 | -0.0009 | 0.00 | -0.0188 | 0.00 | -- | -- | -- | -976.60 | -1,219.29 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 44.29 | -- | -- | -- |
| Health Advance Inc | -100.00bn | -100.00bn | 122.62k | 3.00 | -- | 0.0284 | -- | -- | -- | -- | -- | 0.0212 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0356 | -- | 100.00 | -- | -21.75 | -- | -- | -- |
| Seelos Therapeutics Inc | 2.01m | 4.09m | 170.02k | 8.00 | 0.0024 | -- | -- | 0.0844 | 156.15 | 156.15 | 22.91 | -135.50 | 0.2823 | -- | 6.51 | 134,266.70 | 57.34 | -180.05 | -- | -386.76 | -- | -- | 203.13 | -9,612.88 | -- | -608.33 | -- | -- | -- | -- | 48.48 | -- | -- | -- |
| Propanc Biopharma Inc | 0.00 | -1.87m | 236.97k | 1.00 | -- | -- | -- | -- | -0.0372 | -0.0372 | 0.00 | -0.006 | 0.00 | -- | -- | -- | -1,495.00 | -4,082.63 | -- | -- | -- | -- | -- | -- | -- | -2.55 | -- | -- | -- | -- | 35.61 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| AdvisorShares Investments LLCas of 31 Oct 2024 | 152.44k | 13.56% |
| Modera Wealth Management LLCas of 30 Sep 2024 | 10.81k | 0.96% |
| UBS Securities LLCas of 30 Sep 2024 | 8.48k | 0.75% |
| Geode Capital Management LLCas of 30 Sep 2024 | 2.17k | 0.19% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 437.00 | 0.04% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 200.00 | 0.02% |
| Tower Research Capital LLCas of 30 Sep 2024 | 95.00 | 0.01% |
| BlackRock Fund Advisorsas of 08 Nov 2024 | 43.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 30 Sep 2024 | 32.00 | 0.00% |
| JPMorgan Securities LLC (Investment Management)as of 30 Sep 2024 | 31.00 | 0.00% |
